A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.

被引：0
|
作者：
Pectasides, Dimitrios G.
Karavasilis, Vasilios
Kotoula, Vassiliki
Samantas, Epaminontas
Alexopoulou, Zoi
Zagouri, Flora
Syrigos, Konstantinos N.
Koureas, Andreas
Dionysopoulos, Dimitrios
Lazaridis, Georgios
Efstratiou, Ioannis
Apessou, Dimitra
Pentheroudakis, George E.
Papaxoinis, George
Fountzilas, George
机构：
[1] Hellen Cooperat Oncol Grp HeCOG, Athens, CT, Greece
[2] Hlth Data Specialists Ltd, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e14563
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14563
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [32] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
    Caglayan Geredeli
    Nurgul Yasar
    World Journal of Surgical Oncology, 16
  • [33] Phase IB/II first line panitumumab, irinotecan, trifluridine/tipiracil in RAS wild-type patients with metastatic colorectal cancer: PIT study.
    Price, Timothy Jay
    Joshi, Rohit
    Karapetis, Christos Stelios
    Cooper, Pam
    Hocking, Chris
    Singhal, Nimit
    Townsend, Amanda Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Panitumumab after progression on cetuximab in KRAS wild-type metastatic colorectal cancer patients: a single institution experience
    Marino, Antonella
    Caliolo, Chiara
    Sponziello, Francesco
    Nacci, Angelo
    Quaranta, Annamaria
    Mazzoni, Enrica
    Lutrino, Stefania Eufemia
    Rizzo, Pietro
    Calvani, Nicola
    Orlando, Laura
    Schiavone, Paola
    Fedele, Palma
    D'Amico, Maria
    Chetri, Maria Concetta
    Cinefra, Margherita
    Ferrara, Pasqualinda
    Cinieri, Saverio
    TUMORI JOURNAL, 2015, 101 (05): : 524 - 528
  • [35] FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
    Geredeli, Caglayan
    Yasar, Nurgul
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [36] PIT Study Design: Phase IB/II First Line Panitumumab, Irinotecan, Trifluridine/Tipiracil in RAS Wild-Type Patients with Metastatic Colorectal Cancer
    Price, T.
    Rico, G. Tapia
    Williams, J.
    Yeend, S.
    Lo, L.
    Patel, D.
    Tebbutt, N.
    Shapiro, J.
    Burge, M.
    Gebski, V.
    Townsend, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 72 - 72
  • [37] Phase II study of combination ipilimumab, nivolumab, and panitumumab in patients with KRAS, NRAS, and BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
    Lee, Michael
    Loehrer, Patrick
    Imanirad, Iman
    Cohen, Stacey
    Ciombor, Kristen
    Carlson, Cheryl
    Sanoff, Hanna
    McRee, Autumn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [38] Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope Elizabeth
    Morse, Michael
    Blobe, Gerard C.
    Zafar, Yousuf
    Hsu, Shiaowen David
    Arrowood, Christy
    Ley, Sherri Ha
    Dropkin, Evan
    Niedzwiecki, Donna
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] PRIMARY ANALYSIS OF A PHASE II, SINGLE-ARM STUDY (20060314) COMBINING PANITUMUMAB WITH FOLFIRI IN THE FIRST LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Koehne, C. H.
    Mineur, L.
    Greil, R.
    Letocha, H.
    Thaler, J.
    Hofheinz, R.
    Fernebro, E.
    Gamelin, E.
    Wright, L.
    Karthaus, M.
    ANNALS OF ONCOLOGY, 2010, 21 : I51 - I51
  • [40] A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)
    Ding, K.
    Liu, Y.
    Du, J.
    Zhu, Y.
    Xu, D.
    Li, J.
    Liao, X.
    He, J.
    Wang, J.
    Liu, Z.
    Sun, L.
    Xiao, Q.
    Wang, J.
    Cao, H.
    Cai, Y.
    Cai, C.
    Jin, Z.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S545 - S545
12345